Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density1

Overview of attention for article published in JCEM, February 2000

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

policy: 3 policy sources

Readers on

mendeley: 41 Mendeley

So far, Altmetric has seen 3 policy documents that reference this research output.

Bisphosphonate Drugs for the Treatment of Osteoporosis in Post-Menopausal Women - Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Wome

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 01 Jun 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Bisphosphonates for treating osteoporosis: Committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 03 Jul 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Designing Efficient Systematic Reviews Using Economical Allocation, Creation and Synthesis of Medical Evidence

Cited by RAND Corporation on 01 Oct 2014

RAND Corporation is an American nonprofit global policy think tank created in 1948 by Douglas Aircraft Company to offer research and analysis to the United States Armed Forces. It is financed by the U.S. government and private endowment, corporations, universities and private individuals.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.